The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer

BACKGROUND: Bicalutamide is a nonsteroidal antiandrogen widely used as a first-line clinical treatment for advanced prostate cancer (PCa). Although patients initially show effective responses to bicalutamide treatment, resistance to bicalutamide frequently occurs and leads to the development of cast...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Lei, Peng, Yanfei, Yang, Kuo, Cao, Jiasong, Du, Xiaoling, Liang, Zhixian, Shi, Jiandang, Zhang, Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661764/
https://www.ncbi.nlm.nih.gov/pubmed/36376959
http://dx.doi.org/10.1186/s12964-022-00979-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661764/
https://www.ncbi.nlm.nih.gov/pubmed/36376959
http://dx.doi.org/10.1186/s12964-022-00979-0

Ejemplares similares